Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The product is expected to be launched in December 2023
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The plant is yet to start commercial operations
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Subscribe To Our Newsletter & Stay Updated
